BACKGROUND: Diabetes mellitus (DM) increases the risk for cancer at almost all sites, but data on the association with prostate cancer are inconsistent. METHODS: We assessed the risk of a prostate cancer diagnosis among men with type 2 (T2)DM in a nationwide population-based case-control study including 44,352 men with prostate cancer identified through the Prostate Cancer data Base Sweden (PCBaSe) between 2002 and 2006 and 221,495 age-matched men from the general population. RESULTS: Overall, the risk of prostate cancer among men with T2DM was lower than among men without T2DM [OR, 0.80; 95% confidence interval (CI), 0.76-0.85]. The risk decreased with longer disease duration and was observed across all tumor risk categories, although most clearly among men with low risk tumors (OR, 0.71; 95% CI, 0.64-0.80). The risk for prostate cancer was reduced among diabetic men on dietary treatment only (OR, 0.89; 95% CI, 0.80-0.99) but more markedly among men on oral hypoglycemic agents (OR, 0.80; 95% CI, 0.74-0.87) and insulin (OR, 0.72; 95% CI, 0.69-0.81). Obese diabetic men (BMI > 30 kg/m(2)) showed a reduced risk (OR, 0.72; 95% CI, 0.65-0.80) compared with men without diabetes. There was a trend of decreasing risk with increasing levels of HbA1c (P < 0.05). CONCLUSIONS: This nationwide study confirmed a reduced risk of being diagnosed with prostate cancer among men with T2DM, especially for low-risk tumors. An altered hormonal milieu is a plausible explanation, although the possibility of decreased prostate cancer detection among diabetic men cannot be ruled out. IMPACT: This is the largest study to examine the association between T2DM and prostate cancer accounting for tumor risk group and diabetes treatment.
RCT Entities:
BACKGROUND:Diabetes mellitus (DM) increases the risk for cancer at almost all sites, but data on the association with prostate cancer are inconsistent. METHODS: We assessed the risk of a prostate cancer diagnosis among men with type 2 (T2)DM in a nationwide population-based case-control study including 44,352 men with prostate cancer identified through the Prostate Cancer data Base Sweden (PCBaSe) between 2002 and 2006 and 221,495 age-matched men from the general population. RESULTS: Overall, the risk of prostate cancer among men with T2DM was lower than among men without T2DM [OR, 0.80; 95% confidence interval (CI), 0.76-0.85]. The risk decreased with longer disease duration and was observed across all tumor risk categories, although most clearly among men with low risk tumors (OR, 0.71; 95% CI, 0.64-0.80). The risk for prostate cancer was reduced among diabeticmen on dietary treatment only (OR, 0.89; 95% CI, 0.80-0.99) but more markedly among men on oral hypoglycemic agents (OR, 0.80; 95% CI, 0.74-0.87) and insulin (OR, 0.72; 95% CI, 0.69-0.81). Obese diabeticmen (BMI > 30 kg/m(2)) showed a reduced risk (OR, 0.72; 95% CI, 0.65-0.80) compared with men without diabetes. There was a trend of decreasing risk with increasing levels of HbA1c (P < 0.05). CONCLUSIONS: This nationwide study confirmed a reduced risk of being diagnosed with prostate cancer among men with T2DM, especially for low-risk tumors. An altered hormonal milieu is a plausible explanation, although the possibility of decreased prostate cancer detection among diabeticmen cannot be ruled out. IMPACT: This is the largest study to examine the association between T2DM and prostate cancer accounting for tumor risk group and diabetes treatment.
Authors: Jan Hammarsten; Jan-Erik Damber; Mohammad A Haghsheno; Dan Mellström; Ralph Peeker Journal: Nat Rev Urol Date: 2018-02-13 Impact factor: 14.432
Authors: Aruna V Sarma; James Hotaling; Rodney L Dunn; Patricia A Cleary; Barbara H Braffett; Catherine Kim; Catherine Martin; William Herman; Patricia Gatcomb; Alan M Jacobson; Sarah K Holt; Hunter Wessells Journal: J Urol Date: 2014-09-11 Impact factor: 7.450
Authors: Thomas Höfner; Martin Zeier; Gencay Hatiboglu; Christian Eisen; Gita Schönberg; Boris Hadaschik; Dogu Teber; Stefan Duensing; Andreas Trumpp; Markus Hohenfellner; Sascha Pahernik Journal: World J Urol Date: 2013-12-27 Impact factor: 4.226
Authors: Kerri Beckmann; Danielle Crawley; William G Nelson; Elizabeth A Platz; Elizabeth Selvin; Mieke Van Hemelrijck; Sabine Rohrmann Journal: Cancer Causes Control Date: 2022-01-21 Impact factor: 2.532
Authors: Sara Lindström; Hilary Finucane; Brendan Bulik-Sullivan; Fredrick R Schumacher; Christopher I Amos; Rayjean J Hung; Kristin Rand; Stephen B Gruber; David Conti; Jennifer B Permuth; Hui-Yi Lin; Ellen L Goode; Thomas A Sellers; Laufey T Amundadottir; Rachael Stolzenberg-Solomon; Alison Klein; Gloria Petersen; Harvey Risch; Brian Wolpin; Li Hsu; Jeroen R Huyghe; Jenny Chang-Claude; Andrew Chan; Sonja Berndt; Rosalind Eeles; Douglas Easton; Christopher A Haiman; David J Hunter; Benjamin Neale; Alkes L Price; Peter Kraft Journal: Cancer Epidemiol Biomarkers Prev Date: 2017-06-21 Impact factor: 4.254
Authors: Elizabeth A Tindall; M S Riana Bornman; Smit van Zyl; Alpheus M Segone; L Richard Monare; Philip A Venter; Vanessa M Hayes Journal: BMC Urol Date: 2013-12-29 Impact factor: 2.264